On the stock market since 2015, it operates in the world of health and science. It has 4,700 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 17% a year over the last 4 years. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades below its recent peak — about 10% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 18% a year on average.
There is $544.8M in the vault; even if every debt were paid off, $325.1M would remain.
The company’s market value is 72 times its annual profit. Even a small disappointment could hit the price hard.
Over the last 12 months, executives reported 69 sells against just 18 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, PEN sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: PEN is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.